$TXMD
TherapeuticsMD, Inc.

2023 Q2 Form 10-K Financial Statement

#000156459023005514 Filed on April 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022
Revenue $437.0K $1.152M $69.96M
YoY Change -98.47% -93.83% -19.54%
Cost Of Revenue $0.00 -$11.99M $1.397M
YoY Change -100.0% -353.13% -92.58%
Gross Profit $437.0K $13.14M $68.57M
YoY Change -98.17% -5.72% 0.67%
Gross Profit Margin 100.0% 1140.89% 98.0%
Selling, General & Admin $2.781M $2.458M $57.90M
YoY Change -93.23% -94.87% -71.16%
% of Gross Profit 636.38% 18.7% 84.45%
Research & Development $0.00
YoY Change -100.0%
% of Gross Profit 0.0%
Depreciation & Amortization $0.00 -$1.988M $600.0K
YoY Change -100.0% -298.4% -25.0%
% of Gross Profit 0.0% -15.13% 0.88%
Operating Expenses $2.909M -$63.34M $67.38M
YoY Change -93.18% -228.39% -67.59%
Operating Profit -$2.472M $76.48M $1.191M
YoY Change -86.88% -316.09% -100.85%
Interest Expense $45.00K $36.07M
YoY Change -99.62% 9.56%
% of Operating Profit 3028.13%
Other Income/Expense, Net $58.00K -$100.5M -$117.0K
YoY Change -99.96% -1256587.5% -99.64%
Pretax Income -$2.414M -$33.51M $1.074M
YoY Change -102.14% -21.99% -100.62%
Income Tax -$290.0K $0.00
% Of Pretax Income 0.0%
Net Earnings -$2.414M $77.70M $112.0M
YoY Change -102.15% -280.87% -164.96%
Net Earnings / Revenue -552.4% 6744.97% 160.08%
Basic Earnings Per Share -$0.24 $12.41
Diluted Earnings Per Share -$0.24 $8.19 $11.96
COMMON SHARES
Basic Shares Outstanding 9.953M 9.467M 9.028M
Diluted Shares Outstanding 10.22M 9.366M

Balance Sheet

Concept 2023 Q2 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.73M $38.07M $38.07M
YoY Change -47.8% -41.55% -41.55%
Cash & Equivalents $49.32M $64.91M
Short-Term Investments
Other Short-Term Assets $4.846M $17.28M $17.28M
YoY Change -76.18% 63.86% 63.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.61M $55.35M $55.35M
YoY Change -80.11% -53.67% -53.67%
LONG-TERM ASSETS
Property, Plant & Equipment $39.00K $78.00K $7.658M
YoY Change -94.51% -93.49% -18.82%
Goodwill
YoY Change
Intangibles $6.767M $6.943M
YoY Change -82.52% -82.78%
Long-Term Investments
YoY Change
Other Assets $254.0K $253.0K $253.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $34.08M $35.11M $35.11M
YoY Change -28.41% -29.79% -29.79%
TOTAL ASSETS
Total Short-Term Assets $19.61M $55.35M $55.35M
Total Long-Term Assets $34.08M $35.11M $35.11M
Total Assets $53.69M $90.46M $90.46M
YoY Change -63.28% -46.62% -46.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.508M $2.162M $2.162M
YoY Change -89.21% -89.36% -89.36%
Accrued Expenses $4.573M $17.24M $17.24M
YoY Change -91.29% -57.63% -57.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $14.36M $46.84M $46.84M
YoY Change -91.24% -81.48% -81.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.189M $1.107M $8.476M
YoY Change 114.62% -48.25% -16.92%
Total Long-Term Liabilities $1.189M $1.107M $8.476M
YoY Change 114.62% -48.25% -16.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.36M $46.84M $46.84M
Total Long-Term Liabilities $1.189M $1.107M $8.476M
Total Liabilities $22.49M $55.32M $55.32M
YoY Change -86.94% -78.98% -78.98%
SHAREHOLDERS EQUITY
Retained Earnings -$945.4M -$939.4M
YoY Change -4.32% -10.65%
Common Stock $976.6M $974.5M
YoY Change 1.51% 1.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.20M $35.14M $35.14M
YoY Change
Total Liabilities & Shareholders Equity $53.69M $90.46M $90.46M
YoY Change -63.28% -46.62% -46.62%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$2.414M $77.70M $112.0M
YoY Change -102.15% -280.87% -164.96%
Depreciation, Depletion And Amortization $0.00 -$1.988M $600.0K
YoY Change -100.0% -298.4% -25.0%
Cash From Operating Activities -$4.670M $59.77M -$4.078M
YoY Change -69.68% -251.1% -97.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $37.00K $355.0K
YoY Change -100.0% -102.44% 944.12%
Acquisitions
YoY Change
Other Investing Activities $0.00 $81.20M $223.8M
YoY Change -100.0%
Cash From Investing Activities $0.00 $81.16M $223.5M
YoY Change -100.0% -5460.83% -10153.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.454M
YoY Change -98.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.151M -129.9M -235.2M
YoY Change -100.96% -9704.43% -281.55%
NET CHANGE
Cash From Operating Activities -4.670M 59.77M -4.078M
Cash From Investing Activities 0.000 81.16M 223.5M
Cash From Financing Activities 1.151M -129.9M -235.2M
Net Change In Cash -3.519M 10.99M -15.81M
YoY Change -149.09% -127.66% 2.87%
FREE CASH FLOW
Cash From Operating Activities -$4.670M $59.77M -$4.078M
Capital Expenditures $0.00 $37.00K $355.0K
Free Cash Flow -$4.670M $59.74M -$4.433M
YoY Change -69.53% -257.02% -96.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
951 Yamato Road,
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Auditor Location
AuditorLocation
Miami, Florida
CY2022Q4 us-gaap Cash
Cash
38067000
CY2021Q4 us-gaap Cash
Cash
64907000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57903000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
80748000
CY2021 us-gaap Operating Expenses
OperatingExpenses
80748000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-79577000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
111997000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
188269000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-939363000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35143000
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1397000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1402000
CY2021 us-gaap Gross Profit
GrossProfit
1171000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2573000
CY2022 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0233535
CY2022 dei Trading Symbol
TradingSymbol
TXMD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9498000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9498000
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000025743
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M6D
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity File Number
EntityFileNumber
001-00100
CY2022 dei Entity Registrant Name
EntityRegistrantName
THERAPEUTICSMD, INC.
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
CY2022 dei City Area Code
CityAreaCode
561
CY2022 dei Local Phone Number
LocalPhoneNumber
961-1900
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
87323238
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9953290
CY2022 dei Auditor Firm
AuditorFirmId
248
CY2022 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
11250000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6034000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5859000
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
48702000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
55351000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
119468000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
823000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6943000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7144000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7580000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8234000
CY2022Q4 txmd Royalty Receivable Long Term
RoyaltyReceivableLongTerm
20253000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
33550000
CY2022Q4 us-gaap Assets
Assets
90458000
CY2021Q4 us-gaap Assets
Assets
169472000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2162000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3373000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18846000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13338000
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
25831000
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
47911000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46839000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
252891000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7369000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8063000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1107000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2139000
CY2022Q4 us-gaap Liabilities
Liabilities
55315000
CY2021Q4 us-gaap Liabilities
Liabilities
263093000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8598000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8598000
CY2022 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
50-for-1 reverse stock split
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
974497000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
957730000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1051360000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-93621000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90458000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169472000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69963000
CY2022 us-gaap Gross Profit
GrossProfit
68566000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
9472000
CY2022 us-gaap Operating Expenses
OperatingExpenses
67375000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
1191000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-117000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
272000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-117000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
272000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1074000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79305000
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1074000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-79305000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
110923000
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-93110000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172415000
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.12
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-9.96
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
12.29
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-11.70
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
12.41
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-21.66
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.11
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-9.96
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
11.84
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-11.70
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.96
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-21.66
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9028000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7960000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9366000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7960000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
111997000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172415000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
111997000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-172415000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-124001000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
184115000
CY2021 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
278000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
233000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18125000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172415000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-93621000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2454000
CY2022 txmd Stock Issued During Period Of Lender Warrants
StockIssuedDuringPeriodOfLenderWarrants
2727000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
14000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11572000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
111997000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35143000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
111997000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172415000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
110923000
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-93110000
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1074000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-79305000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1193000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
736000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
11572000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
18125000
CY2022 txmd Make Whole Payment Accretion
MakeWholePaymentAccretion
354000
CY2022 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-40000
CY2021 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
720000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-620000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1125000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7636000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1211000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1062000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4262000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4639000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-121000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2139000
CY2022 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
8285000
CY2021 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
24172000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
9359000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-55133000
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
355000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2189000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-355000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2223000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2454000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
184115000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
322000
CY2022 txmd Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan
ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan
14000
CY2021 txmd Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan
ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan
233000
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
219432000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
50000000
CY2022 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
21684000
CY2022 us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
38657000
CY2022 us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
3322000
CY2022 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
2969000
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1622000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5118000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-235206000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129552000
CY2022 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-13437000
CY2021 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-87560000
CY2022 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
223834000
CY2021 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0
CY2022 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0
CY2021 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0
CY2022 us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
210397000
CY2021 us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
-87560000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-15805000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-15364000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64907000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79019000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
215000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
1467000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49317000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65122000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
13545000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
25068000
CY2022 txmd Warrants Issued In Relation To Debt Financing Agreement
WarrantsIssuedInRelationToDebtFinancingAgreement
2727000
CY2022Q4 txmd Purchase Of Transferred Assets And Grant Of Licenses Cash Payment
PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment
140000000.0
CY2022Q4 txmd Payments To Acquire Net Working Capital
PaymentsToAcquireNetWorkingCapital
12100000
CY2022Q4 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
1000000.0
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
outstanding shares of our Common Stock were split at a ratio of 50- for-1
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000.0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000.0
CY2022 us-gaap Depreciation
Depreciation
600000
CY2021 us-gaap Depreciation
Depreciation
400000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Estimates and assumptions</p></td></tr></table></div> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
29300000
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
8400000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8220000
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
140000000
CY2022 txmd Decrease In Royalty Rate On Product By Product Basis
DecreaseInRoyaltyRateOnProductByProductBasis
0.02
CY2022 txmd Inflation Rate Adjusted For Minimal Annual Royalty Payment
InflationRateAdjustedForMinimalAnnualRoyaltyPayment
0.03
CY2022 txmd Present Value Of Annual Minimum Royalty Discount Rate
PresentValueOfAnnualMinimumRoyaltyDiscountRate
0.1045
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2445000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1971000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78000
CY2022Q4 txmd Research And Development Activities
ResearchAndDevelopmentActivities
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
823000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
0
CY2022 txmd Number Of Employees After Workforce Reduction
NumberOfEmployeesAfterWorkforceReduction
1
CY2022 txmd Restructuring Charges Including Discontinued Operations
RestructuringChargesIncludingDiscontinuedOperations
15700000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
9472000
CY2022 txmd Disposal Group Including Discontinued Operation Restructuring Charges
DisposalGroupIncludingDiscontinuedOperationRestructuringCharges
6180000
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Reclassification of prior year presentation</p></td></tr></table></div> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year amounts have been reclassified for consistency with the current year presentation. An adjustment has been made to the consolidated statements of operations for 2022 and 2021 to reclassify commercial operations and vitaCare operations to discontinued operations as both components, in the aggregate, represented a business shift that will have a major effect on the Company’s operations and financial results.</p>
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1167000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2731000
CY2022Q4 txmd Paragraph Four Legal Proceeding Costs
ParagraphFourLegalProceedingCosts
2334000
CY2021Q4 txmd Paragraph Four Legal Proceeding Costs
ParagraphFourLegalProceedingCosts
2304000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2533000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
824000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6034000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5859000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2523000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2794000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1598000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6622000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7854000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1042000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6812000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8541000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1598000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6943000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8186000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1042000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7144000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
337000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
439000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
438000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
438000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
438000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2537000
CY2022Q4 txmd Finite Lived Intangible Assets Amortization Expense Net
FiniteLivedIntangibleAssetsAmortizationExpenseNet
4627000
CY2022 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2021 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8748000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6549000
CY2022Q4 txmd Accrued Contract Termination Costs
AccruedContractTerminationCosts
4700000
CY2022Q4 txmd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
978000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2571000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1390000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1361000
CY2022Q4 txmd Accrued Prepaid Royalty
AccruedPrepaidRoyalty
1011000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1604000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2857000
CY2022Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
18846000
CY2021Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13338000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
13200000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
39700000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
11731000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
188269000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
188269000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
us-gaap Paid In Kind Interest
PaidInKindInterest
2500000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
13545000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
22568000
CY2021 txmd Debt Interest Prepayment Fee
DebtInterestPrepaymentFee
4660000
CY2022 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
22520000
CY2021 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
5689000
CY2022 us-gaap Interest Expense
InterestExpense
36065000
CY2021 us-gaap Interest Expense
InterestExpense
32917000
CY2018Q4 txmd Net Rentable Area Lease
NetRentableAreaLease
56212
CY2018Q4 txmd Rented Area Lease
RentedAreaLease
7561
CY2019Q3 txmd Additional Area Of Lease Occupied
AdditionalAreaOfLeaseOccupied
48651
CY2019Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P11Y
CY2022Q4 txmd Lessee Operating Lease Existence Of Option To Extend Number
LesseeOperatingLeaseExistenceOfOptionToExtendNumber
2
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q2 txmd Additional Area Of Lease Occupied
AdditionalAreaOfLeaseOccupied
6536
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2022 us-gaap Variable Lease Payment
VariableLeasePayment
700000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
2100000
CY2021 us-gaap Variable Lease Payment
VariableLeasePayment
700000
CY2022 us-gaap Sublease Income
SubleaseIncome
400000
CY2022 txmd Number Of Suites Sublease
NumberOfSuitesSublease
2
CY2022 txmd Defined Contribution Plan Vesting Service Period
DefinedContributionPlanVestingServicePeriod
P5Y
CY2022 txmd Defined Contribution Plan Vesting Percentage
DefinedContributionPlanVestingPercentage
1
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
435000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1443000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1477000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1513000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1551000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1590000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4294000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11868000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3109000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8759000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7580000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8234000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1390000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1361000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7369000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8063000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8759000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
9424000
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1413000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2335000
CY2021Q3 txmd Number Of Senior Executives Agreed For Separation Excluding Former Evp And Former Ceo
NumberOfSeniorExecutivesAgreedForSeparationExcludingFormerEVPAndFormerCEO
3
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2022 txmd Defined Contribution Plan Maximum Employer Matching Contribution
DefinedContributionPlanMaximumEmployerMatchingContribution
2000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
95042
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
  (1) The number of PSUs represents the number of PSUs that will vest.      (2) The number of remaining shares of common stock available for future issuance is based on the number of PSUs that will vest.   (3) As of December 31, 2022, outstanding options have exercise prices ranging from $53.5 to $136.5 and will expire on March 30, 2023, due to termination of employees except for awards for one employee and several consultants. Unvested RSUs will vest until July 2024. The unvested PSUs will vest until April 2025.   (4) As of December 31, 2022, outstanding options have exercise prices ranging from $221.5 to $446 and will expire on March 30, 2023, due to termination of employees except for awards for one employee and several consultants.   (5) As of December 31, 2022, outstanding options have exercise prices ranging from $90 to $446 and will expire on March 30, 2023 due to termination of employees except for awards for one employee and several consultants.  
CY2021Q3 txmd Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Eligible Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceEligibleOptions
250.5
CY2021Q3 txmd Number Of Eligible Employees Elected To Exchange Eligible Options
NumberOfEligibleEmployeesElectedToExchangeEligibleOptions
69
CY2021Q3 txmd Share Based Compensation Arrangement By Share Based Payment Options Granted To Purchase Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentOptionsGrantedToPurchaseCommonStock
89860
CY2021Q3 txmd Percentage Of Shares Of Common Stock Underlying Eligible Options
PercentageOfSharesOfCommonStockUnderlyingEligibleOptions
0.915
CY2021Q3 txmd Number Of Annual Installments Vest
NumberOfAnnualInstallmentsVest
3
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
476000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
240.00
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
152000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
397000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
253.00
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
117000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
60.50
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
61000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
101000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
300.50
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
21000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
201.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
353000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
225.98
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
336000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
230.93
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
94.99
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
177000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
226.56
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
172000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
228.28
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
170000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
229.43
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11600000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18100000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
700000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
224660000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8590000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
17698000
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
19707000
CY2021Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
20391000
CY2022Q4 txmd Deferred Tax Asset Gain On Sale Of Intellectual Property
DeferredTaxAssetGainOnSaleOfIntellectualProperty
-3624000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
69963000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2573000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
1074000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-79305000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 txmd Effective Income Tax Rate Discontinued Operations
EffectiveIncomeTaxRateDiscontinuedOperations
0.005
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 txmd Effective Income Tax Rate Discontinued Operations
EffectiveIncomeTaxRateDiscontinuedOperations
0
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
640000000.0
CY2022 txmd Net Operating Loss Carryforwards Term
NetOperatingLossCarryforwardsTerm
P20Y
CY2022 txmd Net Operating Loss Carryforwards Expiration Year
NetOperatingLossCarryforwardsExpirationYear
2031
CY2022 txmd Percentage Of Future Taxable Income
PercentageOfFutureTaxableIncome
0.80
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-32.286
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.178
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
8.352
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.032
CY2022 txmd Effective Income Tax Rate Reconciliation Interest Expense Accretion Percent
EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercent
0.000
CY2021 txmd Effective Income Tax Rate Reconciliation Interest Expense Accretion Percent
EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercent
0.000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
23.685
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.046
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
176631000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
186000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
186000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-1062000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-1250000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
200428000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
261685000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
200428000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
261685000
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1074000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-79305000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
110923000
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-93110000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
111997000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172415000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9028000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7960000
CY2022 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
338000
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9366000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7960000
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.12
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-9.96
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.11
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-9.96
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
12.29
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-11.70
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
11.84
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-11.70
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
273000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
892000

Files In Submission

Name View Source Status
0001564590-23-005514-index-headers.html Edgar Link pending
0001564590-23-005514-index.html Edgar Link pending
0001564590-23-005514.txt Edgar Link pending
0001564590-23-005514-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gfysnhdkbphk000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
txmd-10k_20221231.htm Edgar Link pending
txmd-20221231.xsd Edgar Link pending
txmd-ex1045_158.htm Edgar Link pending
txmd-ex1046_159.htm Edgar Link pending
txmd-ex1047_471.htm Edgar Link pending
txmd-ex1048_439.htm Edgar Link pending
txmd-ex211_350.htm Edgar Link pending
txmd-ex231_8.htm Edgar Link pending
txmd-ex311_7.htm Edgar Link pending
txmd-ex312_10.htm Edgar Link pending
txmd-ex321_6.htm Edgar Link pending
txmd-ex322_11.htm Edgar Link pending
txmd-ex42_160.htm Edgar Link pending
txmd-20221231_cal.xml Edgar Link unprocessable
txmd-20221231_lab.xml Edgar Link unprocessable
txmd-20221231_def.xml Edgar Link unprocessable
txmd-20221231_pre.xml Edgar Link unprocessable
txmd-10k_20221231_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable